50
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC
As we enter the final leg of 2023, navigating the investment market in biotech continues to be fraught with twists and turns. The IPO market remains tight; there have been a few notable IPOs with mixed performance, a few significant clinical and regulatory successes and even attractive M&A. Though it is never ‘easy’ to get venture investors on board, venture financings continue to happen. However, later stage private financings (Series B & C rounds) are an uphill battle with the specter of “down rounds” overhead. Alternate financing…